Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 12/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 12/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 9/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14018985 | 1.00 | PRKAG1 (0.38) | PRKAG1PRKAB1PRKAA1PRKAA2PRKAB2 | |
| SCHEMBL14018911 | 0.83 | MAPK14 (0.35) | MAPK14 | |
| SCHEMBL4841003 | 0.83 | MAPK14 (0.35) | MAPK14 | |
| SCHEMBL4842360 | 0.82 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL4837999 | 0.78 | MAPK14 (0.43) | MAPK14 | |
| SCHEMBL4841631 | 0.77 | MAPK14 (0.39) | MAPK14 | |
| SCHEMBL14018947 | 0.77 | MAPK14 (0.41) | MAPK14 | |
| SCHEMBL4841405 | 0.77 | MAPK14 (0.41) | MAPK14 | |
| SCHEMBL4836118 | 0.77 | MAPK14 (0.36) | MAPK14 | |
| SCHEMBL4832933 | 0.77 | MAPK14 (0.39) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | claimed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | PRKAG1 413/4885PRKAB1 304/4885PRKAA1 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.